...
首页> 外文期刊>Journal of clinical rheumatology >A beneficial long-term and consistent response to rituximab in the treatment of refractory neutropenia and arthritis in a patient with felty syndrome
【24h】

A beneficial long-term and consistent response to rituximab in the treatment of refractory neutropenia and arthritis in a patient with felty syndrome

机译:对利妥昔单抗有益且长期一致的反应,可用于治疗毡状综合征患者的难治性中性粒细胞减少和关节炎

获取原文
获取原文并翻译 | 示例
           

摘要

Several mechanisms have been proposed in the development of neutropenia in Felty syndrome (FS). However, the contribution of B lymphocytes in the development of the neutropenia is still unknown. As reported in the JCR,1 B-cell depletion therapy may be useful for the therapeutic application in patients with FS. Rituximab, a biological agent, is a chimeric monoclonal antibody specific to human CD20 that targets B lymphocytes.2 We report a case of FS in which our patient was treated long term successfully with rituximab and displayed continued improvement.
机译:在Felty综合征(FS)的中性粒细胞减少症的发展中已提出了几种机制。然而,B淋巴细胞在中性粒细胞减少症的发展中的贡献仍然未知。如JCR报道,1 B细胞耗竭疗法可能对FS患者的治疗应用有用。利妥昔单抗是一种生物制剂,是一种针对人CD20的针对B淋巴细胞的嵌合单克隆抗体。2我们报道了一例FS患者,该患者长期接受利妥昔单抗治疗并表现出持续的改善。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号